This article has been corrected: Due to errors in figure preparation, the AZ-treated (72 hr) images (row 1, panel 2), is an accidental duplicate of the 'CTRL' image in row 3, panel 1 of Figure 1A. The corrected Figure 1A, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Erratum: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/ Akt/mTOR survival pathway and inducing apoptosis (Oncotarget. (2021) 12 (1470–1489) DOI: 10.18632/oncotarget.28011)
Fabrizio F. P.;
2022-01-01
Abstract
This article has been corrected: Due to errors in figure preparation, the AZ-treated (72 hr) images (row 1, panel 2), is an accidental duplicate of the 'CTRL' image in row 3, panel 1 of Figure 1A. The corrected Figure 1A, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
